Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
LEXINGTON, Mass. - Agenus Inc. (Agenus), a leading developer of immunological agents for cancer treatment, has announced that a novel analysis from the Phase 1b trial of botensilimab in combination with balstilimab (BOT/BAL) in relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024.
The presentation at the ASCO Annual Meeting will provide important insights into the potential of botensilimab and balstilimab combination therapy for patients with relapsed/refractory microsatellite stable colorectal cancer. This novel analysis will shed light on the efficacy and safety of this treatment option, particularly for those without active liver metastases.
Colorectal cancer is a prevalent and aggressive form of cancer, and there is a dire need for effective treatments. The Phase 1b trial of botensilimab and balstilimab in relapsed/refractory microsatellite stable colorectal cancer aims to address this unmet need. The trial evaluates the safety and efficacy of the combination therapy in patients who have not responded to previous treatments and do not have active liver metastases.
Agenus Inc. has been a frontrunner in developing novel immunological agents for the treatment of cancer. The company’s dedication to research and development has resulted in promising breakthroughs in the field. The upcoming presentation at the ASCO Annual Meeting will provide an opportunity for experts and researchers to learn more about the potential of botensilimab and balstilimab in the treatment of relapsed/refractory microsatellite stable colorectal cancer.
Additionally, Agenus Inc. recorded a substantial revenue increase of 20.88% year on year. This growth demonstrates the success of the company’s efforts in the development and commercialization of their immunological agents. The sequential revenue growth of 10.45% further indicates a positive trend for the company.
In conclusion, the presentation of breakthrough data on botensilimab/balstilimab in MSS CRC at the 2024 ASCO Annual Meeting holds great promise for patients with relapsed/refractory microsatellite stable colorectal cancer. Agenus Inc.’s dedication to research and development, as reflected in their revenue growth, highlights the company’s potential as a leading player in the field of cancer therapeutics.
Comments